1. Home
  2. TYRA vs AERO Comparison

TYRA vs AERO Comparison

Compare TYRA & AERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$33.74

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

AERO

Grupo Aeromexico S.A.B.

N/A

Current Price

$15.22

Market Cap

2.4B

ML Signal

N/A

Company Overview

Basic Information
Metric
TYRA
AERO
Founded
2018
1934
Country
United States
Mexico
Employees
N/A
17068
Industry
Biotechnology: Pharmaceutical Preparations
Air Freight/Delivery Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.4B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TYRA
AERO
Price
$33.74
$15.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
7
Target Price
$47.50
$28.57
AVG Volume (30 Days)
749.1K
270.0K
Earning Date
05-06-2026
04-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$11.85
Revenue Next Year
N/A
$4.57
P/E Ratio
N/A
$7.95
Revenue Growth
N/A
N/A
52 Week Low
$8.75
$12.26
52 Week High
$40.65
$23.05

Technical Indicators

Market Signals
Indicator
TYRA
AERO
Relative Strength Index (RSI) 43.61 48.59
Support Level $33.29 $14.44
Resistance Level $33.99 $16.95
Average True Range (ATR) 1.98 0.72
MACD -0.02 -0.09
Stochastic Oscillator 30.44 37.64

Price Performance

Historical Comparison
TYRA
AERO

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About AERO Grupo Aeromexico S.A.B.

Grupo Aeromexico SAB de CV engages in providing air transport services for passengers, goods, and cargo, as well as loyalty program services, training and management services, franchise systems commercialization, and the management of investment in shares. Its services include passenger and cargo transportation, the Club Premier loyalty program, training, charter services, and other aviation-related activities. The company operates through a single operating segment, air transportation, and its geographical presence includes both domestic and international markets, with the majority of revenue coming from the international market.

Share on Social Networks: